Login

Tag: Trulicity

Trulicity

DTC Advertising

OPDP Cites Lilly for Omission of Risk Info in Trulicity Instagram Post

OPDP Cites Lilly for Omission of Risk Info in Trulicity Instagram Post

Jan. 31. 2022 – Presenting drug benefit information without also including risk information in a social media post on Instagram misbrands Eli Lilly’s Trulicity® according to a recent enforcement letter to the company from the FDA’s Office of Prescription Drug Promotion (OPDP). In the Jan. 19 Untitled Letter, OPDP states that it reviewed the post […]

Read more

DTC Advertising

J&J, Lilly Make Voluntary Moves to Share Broader Price Info in DTC TV Ads

J&J, Lilly Make Voluntary Moves to Share Broader Price Info in DTC TV Ads

Feb. 11, 2019 – Last week Johnson & Johnson announced that it would include both the list price of a drug and information about what patients realistically might expect to pay out of pocket for its drugs in direct-to-consumer (DTC) ads by the end of the first quarter, starting with Xarelto, its most-prescribed medication. This […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA privacy regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines